Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.5157) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29).
Quoin Pharmaceuticals Stock Performance
NASDAQ QNRX opened at $4.11 on Thursday. The stock has a market cap of $19.74 million, a P/E ratio of -0.16 and a beta of 1.56. Quoin Pharmaceuticals has a fifty-two week low of $3.25 and a fifty-two week high of $23.50. The stock has a 50 day simple moving average of $5.45 and a two-hundred day simple moving average of $6.18.
Insider Buying and Selling
In related news, Director Anthony Culverwell acquired 6,146 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average price of $4.88 per share, for a total transaction of $29,992.48. Following the acquisition, the director directly owned 40,364 shares of the company’s stock, valued at $196,976.32. This represents a 17.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael Myers bought 20,490 shares of the stock in a transaction on Monday, August 31st. The stock was purchased at an average price of $4.88 per share, with a total value of $99,991.20. Following the completion of the acquisition, the chief executive officer directly owned 37,713 shares in the company, valued at approximately $184,039.44. This trade represents a 118.97% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 57,370 shares of company stock worth $279,966. 7.54% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. Canaccord Genuity Group initiated coverage on Quoin Pharmaceuticals in a research report on Monday, October 19th. They issued a “buy” rating and a $18.00 price objective on the stock. Wall Street Zen raised shares of Quoin Pharmaceuticals to a “sell” rating in a research report on Saturday, October 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Friday, October 16th. Lake Street Capital began coverage on Quoin Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “buy” rating and a $20.00 target price on the stock. Finally, BTIG Research assumed coverage on shares of Quoin Pharmaceuticals in a report on Monday, October 12th. They issued a “buy” rating and a $14.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Quoin Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $17.33.
View Our Latest Stock Analysis on Quoin Pharmaceuticals
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases. The company is primarily pursuing therapies for conditions with significant unmet medical needs, including rare genetic disorders affecting the skin.
Quoin’s lead program is QRX003, a topical lotion being developed for Netherton syndrome, a rare inherited skin disorder associated with impaired skin-barrier function. The company is also developing QRX004, a topical product candidate intended for recessive dystrophic epidermolysis bullosa, a severe genetic skin disease.
Read More
- Five stocks we like better than Quoin Pharmaceuticals
- Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
